Advanced breast cancer

The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension...


The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall...


The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...


The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...


The phase III MONALEESA-3 trial investigated Ribociclib, a cyclin-dependent kinase 4/6 ( CDK4/6 ) inhibitor, plus Fulvestrant as first-line...


Abemaciclib ( Verzenios ) is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive ( HR+...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Balversa ( Erdafitinib ), a treatment...


The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate...


The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy ( BKI ) released a...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


Triple-negative breast cancer ( TNBC ) is an aggressive subtype of breast cancer, often resistant to standard of care therapies....


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The...


The FDA ( US Food and Drug Administration ) has approved Kisqali ( Ribociclib ) for women with hormone-receptor positive,...



The FDA ( Food and Drug Administration ) has granted full approval for Tagrisso ( Osimertinib ) 80mg once-daily tablets,...


Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system...